INVESTOR NOTICE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Y-mAbs Class Action Lawsuit - YMABBusiness Wire • 01/19/23
EQUITY ALERT: Rosen Law Firm Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMABBusiness Wire • 01/19/23
Wolf Popper LLP Announces the Filing of a Class Action Lawsuit Against Y-mAbs Therapeutics, Inc.Newsfile Corp • 01/18/23
Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDAGlobeNewsWire • 01/04/23
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in EuropeGlobeNewsWire • 12/21/22
The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in EuropeGlobeNewsWire • 12/16/22
Y-mAbs Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 12/02/22
Y-mAbs Therapeutics receives 'Neutral' stance from Wedbush after FDA rejection of its pediatric cancer drug applicationProactive Investors • 12/02/22
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License ApplicationGlobeNewsWire • 12/01/22
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/08/22
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/22
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 11/07/22
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Y-mAbs Therapeutics (YMAB) With Significant Losses to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law ViolationsNewsfile Corp • 11/04/22
Y-mAbs Therapeutics Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmNewsfile Corp • 11/03/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/03/22
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022GlobeNewsWire • 11/02/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Y-mAbs Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 11/01/22